John Rieth
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, John Rieth sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
John Rieth: 4 sponsored US clinical trials, 1 recruiting.
John Rieth sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Soft Tissue Sarcoma, with 2 trials.
Upper-quartile sponsor footprint
John Rieth sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Palbociclib and Pembrolizumab in Sarcoma
NCT06113809
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
NCT06660810
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
NCT04599062
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
NCT03957551
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the John Rieth pipeline
1 recruiting of 4 indexed (25% open).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Soft Tissue Sarcoma (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
John Rieth: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
John Rieth sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this John Rieth page
4 registered trials is a research-attention snapshot, not an endorsement of John Rieth or any single study.
- 1 of John Rieth's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Soft Tissue Sarcoma is the condition John Rieth studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Soft Tissue Sarcoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
John Rieth pipeline card: 4 registered trials from official public datasets.Report a data error.